Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its Q1 2021 operational and financial report for the period ended June 30, 2021. The biotech company hit several milestones, including becoming the first psychedelic company to list on the NYSE American LLC stock exchange and raising more than CA$120 million. In addition, Cybin has started the next phase of its digital therapeutics platform, signed an exclusive R&D collaboration agreement with TMS NeuroHealth Centers Inc to establish Mental Health Centers of Excellence, as well as commenced scaling up its European operations and research activities with several academic and clinical research organizations. A recent article quotes Cybin CEO Doug Drysdale as saying, “During the past several months, Cybin has garnered a great deal of attention as an emerging leader in the psychedelic therapeutics space. We believe the molecules we have under development may have the potential to transform the treatment landscape and fill current unmet treatment needs for various psychiatric and neurological conditions.”
To view the full article, visit https://ibn.fm/sRKIC
About Cybin Inc.
Cybin is a leading biotechnology company focused on researching and progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.